Dr. Wang has extensive training and expertise in the field of pediatric magnetic resonance imaging (MRI) and spectroscopy. He's experienced in studying perfused cells/organs, and animal and human models using multiparametric MRI and MRS techniques. For the past 18 years, he has been active in pediatric MRI/MRS research.

Dr. Wang was the CHOP site PI for a multi-centered “NIH MRI Study of Normal Brain Development” using volumetric, T1-mapping, DTI, and MRS technologies. He has collaborated with CHOP and outside institutions in several local and nationwide research studies as an investigator, studying a range of disorders including tumors, iron overload, cystic fibrosis, muscular dystrophy, autism, mitochondrial, and Gaucher’s and Canavan’s diseases.

His current research interests focus on biomarker identification using quantitative 1H, 31P, 13C and 129Xe MRS and MRI, such as T2 mapping, Dixon, and CrCEST (Creatine Chemical Exchange Saturation Transfer) Techniques.

BS, Tamkang University, Taiwan (Chemistry),  1979

MS, Stony Brook University, New York (Physical Chemistry, MRI), 1986

PhD, Stony Brook University, New York (Physical Chemistry, MRI/MRS), 1989

Postdoctoral Research Fellow, Metabolic Magnetic Resonance Research and Computing Center, Department of Radiology, University of Pennsylvania, 1989

Chief, MR Spectroscopy

Research Assistant Professor, University of Pennsylvania

International Society for Magnetic Resonance in Medicine, 2001-

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

• National Institutes of Health
• 2015 - 2020
• The objectives of this study is to validate the potential of noninvasive magnetic resonance imaging and spectroscopy to monitor disease progression and to serve as a surrogate outcome measure for clinical trials in Duchenne muscular dystrophy.
• Principal Investigator: Vandenborne

Magnetic Resonance Clinical Trial

• Italfarmaco Study sponsored by University of Florida
• 2016 -2020
• A randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne muscular dystrophy .
• Subcontract Principal Investigator: Wang

NAD+ Precursor Supplementation with Exercise Training to Improve Aerobic Capacity in Friedreich's Ataxia.

• National Institutes of Health
• 2020 - 2024
• Principal Investigator: McCormack

Friedreich Ataxia in Children

• U.S. Food and Drug Administration
• 2017 - 2022
• Principal Investigator: Lynch